On February 3, 2009, the FDA's Cardiovascular and Renal Drugs Advisory Committee unanimously voted to recommend approval of the novel thienopyridine prasugrel for use in ACS patients undergoing PCI. Drs. Nissen, Ohman, Kandzari, Topol, and Steg each give their take on the likely implications for clinical practice and remaining issues of concern in the optimal management of patients with ACS.

Similar posts: cardiovascular disease